Chongqing Zhifei Bio Products (SHE:300122) — Market Cap & Net Worth
Market Cap & Net Worth: Chongqing Zhifei Bio Products (300122)
Chongqing Zhifei Bio Products (SHE:300122) has a market capitalization of $4.28 Billion (CN¥29.23 Billion) as of September 16, 2026. Listed on the SHE stock exchange, this China-based company holds position #3942 globally and #569 in its home market, demonstrating a -8.06% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Chongqing Zhifei Bio Products's stock price CN¥12.21 by its total outstanding shares 2393789747 (2.39 Billion). Also see Chongqing Zhifei Bio Products total assets for a full breakdown of the balance sheet.
Chongqing Zhifei Bio Products Market Cap History: 2015 to 2026
Chongqing Zhifei Bio Products's market capitalization history from 2015 to 2026. Data shows growth from $3.85 Billion to $4.28 Billion (3.24% CAGR). Also see 300122 operating cash flow for how efficiently the company converts equity into cash flow.
Index Memberships
Chongqing Zhifei Bio Products is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ChiNext
CNT
|
$1.14 Trillion | 0.37% | #55 of 100 |
Weight: Chongqing Zhifei Bio Products's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Chongqing Zhifei Bio Products Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Chongqing Zhifei Bio Products's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of Chongqing Zhifei Bio Products for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.74x
Chongqing Zhifei Bio Products's market cap is 0.74 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $3.50 Billion | $445.95 Million | $32.52 Million | 7.85x | 107.63x |
| 2017 | $5.97 Billion | $1.34 Billion | $432.28 Million | 4.45x | 13.81x |
| 2018 | $8.26 Billion | $5.23 Billion | $1.45 Billion | 1.58x | 5.69x |
| 2019 | $10.72 Billion | $10.59 Billion | $2.37 Billion | 1.01x | 4.53x |
| 2020 | $32.02 Billion | $15.19 Billion | $3.30 Billion | 2.11x | 9.70x |
| 2021 | $27.05 Billion | $30.65 Billion | $10.21 Billion | 0.88x | 2.65x |
| 2022 | $19.17 Billion | $38.26 Billion | $7.54 Billion | 0.50x | 2.54x |
| 2023 | $20.77 Billion | $52.92 Billion | $8.07 Billion | 0.39x | 2.57x |
| 2024 | $9.21 Billion | $26.07 Billion | $2.02 Billion | 0.35x | 4.56x |
| 2025 | $6.61 Billion | $8.96 Billion | -$14.72 Billion | 0.74x | N/A |
Competitor Companies of 300122 by Market Capitalization
Companies near Chongqing Zhifei Bio Products in the global market cap rankings as of September 16, 2026. Review 300122 intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Chongqing Zhifei Bio Products by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Chongqing Zhifei Bio Products Historical Marketcap From 2015 to 2026
Between 2015 and today, Chongqing Zhifei Bio Products's market cap moved from $3.85 Billion to $ 4.28 Billion, with a yearly change of 3.24%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥4.28 Billion | -35.29% |
| 2025 | CN¥6.61 Billion | -28.25% |
| 2024 | CN¥9.21 Billion | -55.66% |
| 2023 | CN¥20.77 Billion | +8.37% |
| 2022 | CN¥19.17 Billion | -29.12% |
| 2021 | CN¥27.05 Billion | -15.52% |
| 2020 | CN¥32.02 Billion | +198.79% |
| 2019 | CN¥10.72 Billion | +29.67% |
| 2018 | CN¥8.26 Billion | +38.46% |
| 2017 | CN¥5.97 Billion | +70.51% |
| 2016 | CN¥3.50 Billion | -9.12% |
| 2015 | CN¥3.85 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Chongqing Zhifei Bio Products was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.28 Billion USD |
| MoneyControl | $4.28 Billion USD |
| MarketWatch | $4.28 Billion USD |
| marketcap.company | $4.28 Billion USD |
| Reuters | $4.28 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Chongqing Zhifei Bio Products
Chongqing Zhifei Biological Products Co., Ltd., a biopharmaceutical company, engages in the research and development, production, sale, and distribution of vaccine and biological products in China. The company offers recombinant COVID-19 vaccine; recombinant mycobacterium tuberculosis fusion protein products; group A and C meningococcal polysaccharide vaccine; ACYW135 meningococcal polysaccharide… Read more